Analysts’ Top Healthcare Picks: CVS Health (CVS), Rhythm Pharmaceuticals (RYTM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CVS Health (CVS – Research Report) and Rhythm Pharmaceuticals (RYTM – Research Report) with bullish sentiments.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

CVS Health (CVS)

In a report released yesterday, Charles Weston from RBC Capital maintained a Buy rating on CVS Health. The company’s shares closed last Wednesday at $80.67, close to its 52-week high of $80.75.

According to TipRanks.com, Weston is ranked #9738 out of 10089 analysts.

CVS Health has an analyst consensus of Strong Buy, with a price target consensus of $86.28, a 7.9% upside from current levels. In a report issued on October 14, Goldman Sachs also initiated coverage with a Buy rating on the stock with a $91.00 price target.

See the top stocks recommended by analysts >>

Rhythm Pharmaceuticals (RYTM)

Morgan Stanley analyst Michael Ulz maintained a Buy rating on Rhythm Pharmaceuticals today and set a price target of $129.00. The company’s shares closed last Wednesday at $109.35.

According to TipRanks.com, Ulz is a 4-star analyst with an average return of 5.8% and a 45.5% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Aardvark Therapeutics, Inc., Kyverna Therapeutics, Inc., and Arrowhead Pharmaceuticals. ;'>

Currently, the analyst consensus on Rhythm Pharmaceuticals is a Strong Buy with an average price target of $121.00.

Read More on CVS:

Disclaimer & DisclosureReport an Issue

• CVS Pharmacy completes acquisition of Rite Aid assets nationwide
• UnitedHealth Stock (UNH) Scores Goldman Sachs’ Buy Rating, Truist Lifts Price Target
• AMD upgraded, Micron downgraded: Wall Street’s top analyst calls
• CVS Health price target raised to $92 from $84 at Truist
• CVS Health price target raised to $89 from $82 at Morgan Stanley